



Certificate No. : M-0186

Dr Lalchandani  **abs**
Since 1986

Pathology | Radiology | Consultations

(A Brand of Dr Lalchandani Labs Limited)
(On CGHS Panel)

26/10/2018

To,
Corporate Relationship Department,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400 001
Email: corp.relations@bseindia.com

Ref : Scrip Code: 541299 ; ISIN : INE871Z01013

Sub: Statement of Deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations 2015 for the period ended on 30th September, 2018.

Dear Sir, / Madam,

With reference to the captioned subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(8) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September, 2018.

We request you to kindly take the same on record.

Thanking you,
Yours Faithfully

FOR DR LALCHANDANI LABS LIMITED

DR. LALCHANDANI LABS LIMITED


Mohit Lalchandani **Director**
Whole Time Director
DIN- 07873508




Dr Lalchandani Labs Limited

CIN No. U85320DL2017PLC321605

 M-20, GK-1, Main Road, New Delhi - 110048

 info@lalchandaniplab.com

 011-49057058/9
80-10-689-689

 www.lalchandaniplab.com



STATEMENT OF DEVIATION(S) OR VARIATION(S) UNDER REGULATION 32(1) OF SEBI (LODR) REGULATIONS 2015

In reference to the compliance under regulation 32(1) & (3) of SEBI (LODR) Regulations, 2015. As required under regulation 32(8) of SEBI (LODR) Regulations 2015, the company hereby submit to the Stock Exchange statements of deviation(s) or variation(s) for the half year ended on 30th September, 2018 for the initial public offer (IPO).

With reference to the captioned subject under regulation 32(8) of SEBI (LODR) Regulations 2015, the company hereby submit to the Stock Exchange statements of deviation(s) or variation(s) for the half year ended on 30th September, 2018 for the initial public offer (IPO).

(a) Indicating Deviation(s), if any, in the use of proceeds from the object stated in the offer document or explanatory statement to the notice for the general meeting as applicable;

We hereby inform you that there was no deviation in the utilization of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1) (a) of SEBI (LODR) Regulations 2015 and entire fund raised from the above said issue has been utilized /to be utilized for the purpose as mentioned in the offer document.

(b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds;

We hereby inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 11th April, 2018 issued for Initial Public offering of Securities as per Regulation 32(1)(b) of SEBI (LODR) Regulations 2015.

Thanking you
Yours Faithfully
For Dr Lalchandani Labs Limited

DR. LALCHANDANI LABS LIMITED

Mohit Lalchandani **Director**
Whole Time Director
DIN - 07873508

